Travere's FILSPARI: Nearing FDA Approval for FSGS Patients

FILSPARI (sparsentan) for rare kidney disease FSGS is close to FDA approval, with no advisory committee needed! It's the 1st potential treatment, showing strong trial results by reducing protein in urine and lowering kidney failure risk. PDUFA date: Jan 13, 2026.